Company_Context
Basic Materials
Biological Products, (No Diagnostic Substances)
Institutional analysis of internal capital flows based on SEC Form 4 filings.
Signal_Window
Headline metrics use exact calendar-day windows.
6 directional transactions in 365D
Code P purchases and code S sales are measured from 2025.08.29 — 2026.08.28.
-$974K
Open-market buys minus sales2026.08.04
Latest available filing19
Reporting entities in windowMurphy Nicole
$585Singhal Priya
$734.7KAnalysis of eligible SEC Form 4 activity for BIIB indicates a bearish 365-day signal. The selected window contains transactions from 19 distinct reporting insiders, with aggregate nominal activity of $7.85M.
Open-market purchases minus open-market sales produce a negative net flow of $0.97M. Open-market executions represent the majority of measured nominal activity in this window, making the directional flow more representative of voluntary trading activity.
Murphy Nicole recorded the largest aggregate purchase volume, while Singhal Priya recorded the largest aggregate sale volume. Form 4 activity provides useful ownership context, but it should not be treated as a standalone prediction of future price performance.
Enriched_Research_Context
These indicators use normalized SEC roles, issuer metadata, cluster detection and post-filing market prices already calculated by the data pipeline.
Basic Materials
Biological Products, (No Diagnostic Substances)
0
Clustered open-market purchase records in the recent filing sample.
Recent_Filing_History
This table shows recent filing history and is not restricted by the selected 365D headline signal window.
The 365-day open-market signal is BEARISH, with net flow of $0.97M across 19 reporting insiders in the selected window.
The most recent insider transaction on record was filed on 2026.08.04. InsiderAlpha monitors EDGAR filings and updates this terminal as new Form 4 documents are published.
The selected 365-day window contains 19 distinct reporting insiders with eligible transactions for BIIB. This count changes when a different signal window is selected.
Murphy Nicole
OPEN_MARKET_BUYHead of Pharm Ops and Tech · 2026.02.12
30D
-6.3%
90D
+4.6%
180D
PENDING
Performance uses the latest matured open-market record in this sample. It describes subsequent market movement and does not imply that the filing caused the price change.